查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1677194

罕見疾病治療市場按藥物類型、治療領域、給藥途徑、分銷管道和最終用戶分類 - 2025 年至 2030 年全球預測

Rare Diseases Treatment Market by Drug Type, Therapeutic Area, Route of Administration, Distribution Channel, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2024年罕見疾病治療市場價值將達到196.2億美元，2025年將達216.9億美元，複合年成長率為10.90%，到2030年將達到365.1億美元。

主要市場統計數據
基準年 2024 年 196.2億美元
預計 2025 年 216.9億美元
預測年份 2030 365.1億美元
複合年成長率（%） 10.90％

罕見疾病一直處於醫學研究的前沿，帶來了獨特的挑戰和機會。這些疾病的治療方案的演變以技術的快速進步、監管興趣的增加以及對未滿足的醫療需求的日益認知為標誌。本執行摘要探討了改變治療前景的關鍵因素，平衡了深層的科學挑戰和突破性創新的潛力。

近年來，臨床研究和市場的投資激增，為突破性治療方法和個人化醫療鋪平了道路。該領域的每一次突破不僅為罕見疾病患者帶來希望，也迫使產業領導者重新審視傳統觀念。該報告深入探討了市場區隔、區域動態和重新定義治療格局的新興趨勢等細微層面。隨著產業轉向更有針對性和更有效的治療方案，相關人員面臨著影響罕見疾病管理未來的挑戰和機會。

透過對這些因素進行全面的分析，本摘要為決策者提供了有關該行業發展方向的清晰權威的觀點，並為這一重要醫療保健領域的明智投資和戰略規劃奠定了基礎。

改變罕見疾病治療市場

由於多方面的變化正在重新定義市場範式，因此罕見疾病治療領域正在經歷重大轉型。這些變化的核心是顛覆傳統治療模式的新治療方法的快速出現。藥物開發過程擴大利用從精準醫療到先進生物技術方法的尖端技術，確保治療不僅具有創新性，而且更加以患者為中心。

最近的趨勢是由對研發的大量投資所推動的，這些投資率先將基因療法、免疫療法和其他突破性治療方法融入主流臨床實踐。監管機構正在調整和簡化核准流程，以促進有前景的治療方法的快速部署，同時保持嚴格的安全性和有效性標準。這種轉變伴隨著對患者參與和倡導的更多關注，受罕見疾病影響的患者的聲音決定了研究的重點並影響了政策決策。

簡而言之，醫療保健生態系統正在朝著更靈活、反應更迅速的方向邁進。技術創新、不斷發展的法規和消費者權益保護的整合不僅改變了治療通訊協定，而且還開啟了相關人員之間合作的新時代，從而促進開發更加個人化、更易於獲取和更有效的治療方法。

罕見疾病治療市場的關鍵細分洞察

對罕見疾病治療市場的分析細分，透過從多個觀點細分市場，揭示深刻見解。首先，基於藥物類型的分類透過生物製藥和非生物製藥的角度來審視市場。這種細分凸顯了每個類別相關的不同技術複雜性和監管障礙，有助於理解投資重點和開發平臺的細微差別。

此外，治療領域細分透過分析癌症、心血管疾病、內分泌疾病、感染疾病、代謝疾病、肌肉骨骼疾病和整體情況等疾病的市場，描繪出廣泛而詳細的圖像。每個領域都需要不同的臨床方法和監管策略，但有助於全面了解罕見疾病的治療潛力。

另一個重要的分類是給藥途徑，治療方法分為注射或口服。這種分類強調了患者依從性、藥物生物生物有效性以及藥物傳遞機制固有的挑戰的重要性。市場區隔也延伸到分銷管道，涵蓋醫院藥局、線上藥局和專業藥局環境。這些部分代表了市場範圍、營運物流和患者獲取方面的變化。

最後，基於最終用戶的細分涵蓋了廣泛的利益相關者，包括生物技術和製藥公司、政府和監管機構、醫院和專科診所、患者權益團體和非營利組織、醫生診所和門診病人相關人員以及研究和學術機構。這種多管齊下的方法不僅確定了罕見疾病治療所涉及的多樣化生態系統，而且還強調了每位參與者在推動治療進步方面所發揮的相互關聯作用。

將這些細分見解結合在一起，可以清楚地看出，罕見疾病治療市場並不是一個整體，而是一個複雜的專業領域，每個領域都需要量身定做的策略，並凸顯夥伴關係合作的潛力，以加速提供創新解決方案。

目錄

第 1 章 簡介

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 罕見疾病未滿足的臨床需求推動精準醫療需求
      • 罕見病患病率上升和診斷方法改進將推動市場成長
      • 擴大患者宣傳和支持網路將提高人們對疾病的認知，並提高對新解決方案的需求
    • 限制因素
      • 冗長而繁瑣的核准流程阻礙了創新治療方法的推出
    • 機會
      • 整合數位健康平台和遠端醫療服務，提高病患參與度
      • 與專業研究機構合作並整合人工智慧解決方案
    • 任務
      • 有限的保險覆蓋範圍和限制性報銷政策對市場准入產生負面影響
  • 市場區隔分析
    • 藥物類型：利用生物藥品的變革力量實現有針對性的個人化治療
    • 最終用戶：醫院和專科診所對於結合前沿研究與臨床卓越性發揮越來越重要的作用
  • 波特五力分析
  • PESTEL 分析
    • 政治的
    • 經濟
    • 社會
    • 技術的
    • 合法的
    • 環境

第6章 罕見疾病治療市場（依藥物類型）

  • 生醫藥
  • 非生物藥物

第 7 章 罕見疾病治療市場（依治療領域）

  • 癌症
  • 心血管疾病
  • 內分泌失調
  • 血液系統疾病
  • 感染疾病
  • 代謝紊亂
  • 肌肉骨骼疾病
  • 神經系統疾病

8. 罕見疾病治療市場（依給藥途徑分類）

  • 注射劑
  • 口服

第9章 罕見疾病治療市場依通路分類

  • 醫院藥房
  • 網路藥局
  • 專業藥房

第 10 章 罕見疾病治療市場（依最終使用者分類）

  • 生技及製藥公司
  • 政府和監管機構
  • 醫院和專科診所
  • 病患權益倡導和非營利組織
  • 醫生辦公室和門診中心
  • 研究和學術機構

11. 美洲罕見疾病治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

12. 亞太地區罕見疾病治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

13. 歐洲、中東和非洲罕見疾病治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章 競爭格局

  • 2024 年市場佔有率分析
  • FPNV 定位矩陣，2024 年
  • 競爭情境分析
  • 戰略分析與建議

公司列表

  • AbbVie Inc.
  • ACADIA Pharmaceuticals Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Amgen Inc
  • AstraZeneca PLC
  • Baxter International
  • Bayer AG
  • Biogen Inc.
  • BioMarin Pharmaceutical Inc.
  • Bristol-Myers Squibb Company
  • Editas Medicine, Inc.
  • Eli Lilly and Company
  • F. Hoffmann La Roche Ltd
  • GSK plc
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer, Inc.
  • Regenxbio Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited.
  • United Therapeutics Corporation
  • Vertex Pharmaceutical, Inc.
Product Code: MRR-F25A7181B311

The Rare Diseases Treatment Market was valued at USD 19.62 billion in 2024 and is projected to grow to USD 21.69 billion in 2025, with a CAGR of 10.90%, reaching USD 36.51 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 19.62 billion
Estimated Year [2025] USD 21.69 billion
Forecast Year [2030] USD 36.51 billion
CAGR (%) 10.90%

Rare diseases have long been a frontier in medical research, presenting distinct challenges and opportunities alike. The evolving terrain of treatment options for these conditions is marked by rapid advancements in technology, heightened regulatory focus, and a growing recognition of unmet medical needs. In this executive summary, we explore the key factors reshaping the treatment landscape, striving to balance the deep-rooted scientific challenges with the promise of breakthrough innovations.

Over the past few years, clinical research and market investments have surged, paving the way for transformative therapies and personalized medicine approaches. Each stride in the field not only offers hope to patients with rare conditions but also compels industry leaders to re-examine established conventions. This report delves into the nuanced layers of market segmentation, regional dynamics, and emerging trends that are redefining the therapeutic landscape. As the industry pivots towards more targeted and effective treatment solutions, stakeholders are presented with both challenges and opportunities that will dictate the future of rare diseases management.

By comprehensively analyzing these components, this summary equips decision-makers with a clear and authoritative perspective on where the field is headed, while also laying the groundwork for informed investment and strategic planning in this critical healthcare sector.

Transformative Shifts in the Rare Diseases Treatment Landscape

The realm of rare diseases treatment is undergoing a remarkable transformation, driven by multifaceted shifts that are redefining market paradigms. At the heart of these changes is the rapid emergence of novel therapeutic modalities that break away from conventional treatment frameworks. Drug development processes are increasingly leveraging cutting-edge technologies, from precision medicine to advanced biotechnological approaches, ensuring that treatments are not only innovative but also more patient-centric.

Recent advancements have been fueled by substantial investments in research and development, which have spearheaded the integration of gene therapies, immunotherapies, and other breakthrough interventions into mainstream clinical practice. Regulatory bodies have adapted, streamlining approval processes to facilitate the rapid deployment of promising treatments while maintaining rigorous safety and efficacy standards. This shift is complemented by a growing emphasis on patient engagement and advocacy, where the voices of those affected by rare conditions are driving research priorities and influencing policy decisions.

In essence, the landscape is witnessing a decisive movement towards a more agile and responsive healthcare ecosystem. The convergence of technological innovation, regulatory evolution, and consumer advocacy is not only transforming treatment protocols but also heralding a new era of collaboration among stakeholders, enabling the development of therapies that are more tailored, accessible, and effective.

Key Segmentation Insights in the Rare Diseases Treatment Market

The analytical breakdown of the rare diseases treatment market reveals profound insights by segmenting the landscape according to multiple dimensions. First, when examining classifications based on drug type, the market is studied through the lens of Biological Drugs and Non-Biological Drugs. This differentiation highlights the varying technological complexities and regulatory hurdles associated with each category, offering a nuanced understanding of investment priorities and R&D pipelines.

Additionally, the therapeutic area segmentation paints a broad yet detailed picture, with the market analyzed across conditions such as Cancer, Cardiovascular Conditions, Endocrine Disorders, Hematologic Disorders, Infectious Diseases, Metabolic Disorders, Musculoskeletal Conditions, and Neurological Conditions. Each of these areas demands a distinct clinical approach and regulatory strategy, yet they collectively contribute to a holistic view of the treatment potential within rare diseases.

Another critical segregation involves the route of administration, where treatments are evaluated as either Injectable or Oral formulations. This classification underlines the importance of patient compliance, drug bioavailability, and the inherent challenges in drug delivery mechanisms. Market segmentation also extends to distribution channels, with analyses covering Hospital Pharmacy, Online Pharmacy, and Specialty Pharmacy environments. These distinctions signal variations in market reach, operational logistics, and patient access.

Lastly, the segmentation based on end users spans a wide array of stakeholders, from Biotechnology and Pharmaceutical Companies, Government and Regulatory Bodies, Hospitals and Specialty Clinics, Patient Advocacy Groups and Nonprofits, Physician Practices and Outpatient Centers, to Research and Academic Institutions. This multifaceted approach not only identifies the diverse ecosystem involved in rare diseases treatment but also underscores the interconnected role of each player in driving therapeutic advancements.

By weaving together these segmentation insights, it becomes clear that the rare diseases treatment market is not monolithic but rather a complex tapestry of specialized niches, each demanding bespoke strategies and underscoring the potential for cross-sector partnerships to accelerate the delivery of innovative solutions.

Based on Drug Type, market is studied across Biological Drugs and Non-Biological Drugs.

Based on Therapeutic Area, market is studied across Cancer, Cardiovascular Conditions, Endocrine Disorders, Hematologic Disorders, Infectious Diseases, Metabolic Disorders, Musculoskeletal Conditions, and Neurological Conditions.

Based on Route of Administration, market is studied across Injectable and Oral.

Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Specialty Pharmacy.

Based on End User, market is studied across Biotechnology & Pharmaceutical Companies, Government & Regulatory Bodies, Hospitals & Specialty Clinics, Patient Advocacy Groups & Nonprofits, Physician Practices & Outpatient Centers, and Research & Academic Institutions.

Regional Insights: Navigating the Global Market Landscape

A detailed examination of the rare diseases treatment market further reveals considerable regional distinctions that are critical for strategic planning and investment decisions. In the Americas, robust healthcare infrastructure combined with aggressive funding for research drives a vibrant market characterized by rapid clinical trials and a patient-oriented ethos. These dynamics create an ecosystem where innovation is closely intertwined with policy support and advanced manufacturing capabilities.

Moving to Europe, the Middle East, and Africa, the landscape is marked by a blend of high regulatory standards and diverse market maturity levels. European markets, in particular, benefit from harmonized regulatory frameworks and well-established healthcare systems, which together facilitate the swift adoption of novel treatments. However, markets within the Middle East and Africa also showcase promising growth potential driven by increasing healthcare investments and rising awareness of rare diseases. The regional heterogeneity demands tailored approaches in regulatory compliance and market access to fully harness the available opportunities.

Across the Asia-Pacific region, dynamic economic growth coupled with progressive healthcare policies is spurring significant advancements in rare disease treatment. The region is experiencing a surge in local research initiatives and a growing base of clinical expertise that is rapidly aligning with global standards. The combined influence of consumer demand, enhanced infrastructural capabilities, and targeted government initiatives propels this region into a prominent position on the global stage.

These regional insights emphasize that while the global market is interconnected, distinct regional strategies are essential in addressing specific market challenges and leveraging unique opportunities. By understanding these localized dynamics, stakeholders can adopt more informed and region-specific approaches to expanding their footprint and optimizing therapeutic impact.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Leading Companies Driving Innovation and Growth

The competitive landscape of the rare diseases treatment market is defined by a host of pioneering companies that continue to drive innovation and market growth. Recognized industry entities such as AbbVie Inc., ACADIA Pharmaceuticals Inc., and Alnylam Pharmaceuticals, Inc. have taken center stage by investing heavily in research and advanced biotechnological applications designed to address complex therapeutic needs. These companies, along with Amgen Inc and AstraZeneca PLC, are leveraging large-scale collaborations and patient-centric approaches that challenge traditional treatment paradigms.

Distinguished firms like Baxter International, Bayer AG, and Biogen Inc. have carved out significant market positions by spearheading advanced clinical programs and integrating innovative therapeutic modalities into mainstream practice. Meanwhile, BioMarin Pharmaceutical Inc. and Bristol-Myers Squibb Company are setting benchmarks in their respective niches, ensuring that the pace of innovation continues unabated despite inherent challenges in treating rare conditions. The expertise and adaptive research methodologies of companies such as Editas Medicine, Inc. and Eli Lilly and Company further illuminate the sector's diverse potential.

Notably, industry leaders including F. Hoffmann La Roche Ltd, GSK plc, and Johnson & Johnson Services, Inc. consistently push the boundaries through strategic investments and cross-functional research programs. Their collaborations with Merck KGaA, Novartis AG, and Novo Nordisk A/S underscore a commitment to exploring novel treatment avenues. Pfizer, Inc., Regenxbio Inc., Sanofi SA, Takeda Pharmaceutical Company Limited, United Therapeutics Corporation, and Vertex Pharmaceutical, Inc. are also at the forefront of leveraging breakthrough science to tackle rare diseases.

It is the combined force of these pivotal players that not only fosters a competitive market environment but also ensures a continuous pipeline of innovative products. Their efforts have collectively accelerated the advent and adoption of next-generation therapies, setting the stage for dramatic improvements in patient outcomes. In this environment, strategic collaborations and investment in cutting-edge research remain essential to sustaining market momentum and addressing the rapidly evolving clinical demands associated with rare diseases.

The report delves into recent significant developments in the Rare Diseases Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., ACADIA Pharmaceuticals Inc., Alnylam Pharmaceuticals, Inc., Amgen Inc, AstraZeneca PLC, Baxter International, Bayer AG, Biogen Inc., BioMarin Pharmaceutical Inc., Bristol-Myers Squibb Company, Editas Medicine, Inc., Eli Lilly and Company, F. Hoffmann La Roche Ltd, GSK plc, Johnson & Johnson Services, Inc., Merck KGaA, Novartis AG, Novo Nordisk A/S, Pfizer, Inc., Regenxbio Inc., Sanofi SA, Takeda Pharmaceutical Company Limited., United Therapeutics Corporation, and Vertex Pharmaceutical, Inc.. Actionable Recommendations for Industry Leaders

Industry leaders must adopt a proactive and multifaceted strategy to navigate the rapidly evolving rare diseases treatment landscape. Prioritizing investments in research and development is crucial, particularly in emerging therapeutic areas that promise substantial breakthroughs. Companies should consider forming strategic partnerships and alliances with academic institutions and clinical research organizations to gain early access to innovative ideas and technological advancements.

Moreover, a robust focus on patient engagement and advocacy is imperative. By aligning treatment strategies with patient needs, companies can drive more effective clinical outcomes and foster trust across the healthcare spectrum. Regulatory engagement should also be enhanced to ensure timely approvals and streamline pathways for market entry. Embracing a data-driven approach to market analysis can further reinforce decision-making processes and optimize resource allocation in both research and commercialization efforts.

By following these actionable recommendations, industry stakeholders can position themselves at the forefront of innovation while simultaneously addressing the complex needs of patients with rare diseases.

Conclusion: Strategic Outlook and Future Direction

In conclusion, the rare diseases treatment market stands at a critical juncture, where transformative shifts in research, regulatory adjustments, and strategic market segmentation converge to redefine therapeutic excellence. The detailed analysis of segmentation based on drug type, therapeutic area, route of administration, distribution channel, and end users provides a panoramic view of a market that is as complex as it is promising. At the same time, regional insights reveal distinct dynamics across the Americas, Europe, Middle East and Africa, and Asia-Pacific, highlighting the necessity for tailored market strategies and localized execution.

Forward-looking, the consistent drive towards innovation, underpinned by strategic investments and collaborations among leading companies, lays a robust foundation for sustained growth. As treatments become more personalized and patient outcomes improve, stakeholders are well-positioned to leverage emerging trends and technological advancements. The adoption of clear, actionable recommendations will be key to unlocking future opportunities and meeting the challenges head-on. This strategic overview underscores the importance of informed decision-making and agile adaptation in a landscape where each advancement carries the promise of transforming lives and reshaping the industry as a whole.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing demand for precision medicine driven by unmet clinical needs in rare diseases
      • 5.1.1.2. Rising prevalence and improved diagnosis of rare disorders contributing to accelerated market growth
      • 5.1.1.3. Increasing patient advocacy and support networks that increase disease awareness and demand for new solutions
    • 5.1.2. Restraints
      • 5.1.2.1. Lengthy and multifaceted approval processes delay the introduction of innovative therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Integration of digital health platforms and telemedicine services to increase patient engagement
      • 5.1.3.2. Collaborating with specialized research organizations to integrate artificial intelligence solutions
    • 5.1.4. Challenges
      • 5.1.4.1. Limited insurance coverage and restrictive reimbursement policies that negatively impact market access
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Type: Harnessing the transformative power of biological drugs for targeted and personalized therapeutics
    • 5.2.2. End User: Increasing role of hospitals & specialty clinics in bridging cutting-edge research with clinical excellence
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Rare Diseases Treatment Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Biological Drugs
  • 6.3. Non-Biological Drugs

7. Rare Diseases Treatment Market, by Therapeutic Area

  • 7.1. Introduction
  • 7.2. Cancer
  • 7.3. Cardiovascular Conditions
  • 7.4. Endocrine Disorders
  • 7.5. Hematologic Disorders
  • 7.6. Infectious Diseases
  • 7.7. Metabolic Disorders
  • 7.8. Musculoskeletal Conditions
  • 7.9. Neurological Conditions

8. Rare Diseases Treatment Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Injectable
  • 8.3. Oral

9. Rare Diseases Treatment Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacy
  • 9.3. Online Pharmacy
  • 9.4. Specialty Pharmacy

10. Rare Diseases Treatment Market, by End User

  • 10.1. Introduction
  • 10.2. Biotechnology & Pharmaceutical Companies
  • 10.3. Government & Regulatory Bodies
  • 10.4. Hospitals & Specialty Clinics
  • 10.5. Patient Advocacy Groups & Nonprofits
  • 10.6. Physician Practices & Outpatient Centers
  • 10.7. Research & Academic Institutions

11. Americas Rare Diseases Treatment Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Rare Diseases Treatment Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Rare Diseases Treatment Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Curant Health launches Curant Rare to transform rare and orphan disease care strategies
    • 14.3.2. Healx and Sanofi collaborate to repurpose a discontinued asset for transforming rare disease treatment discovery
    • 14.3.3. AstraZeneca acquisition of Amolyt Pharma to advance treatment for chronic hypoparathyroidism
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. ACADIA Pharmaceuticals Inc.
  • 3. Alnylam Pharmaceuticals, Inc.
  • 4. Amgen Inc
  • 5. AstraZeneca PLC
  • 6. Baxter International
  • 7. Bayer AG
  • 8. Biogen Inc.
  • 9. BioMarin Pharmaceutical Inc.
  • 10. Bristol-Myers Squibb Company
  • 11. Editas Medicine, Inc.
  • 12. Eli Lilly and Company
  • 13. F. Hoffmann La Roche Ltd
  • 14. GSK plc
  • 15. Johnson & Johnson Services, Inc.
  • 16. Merck KGaA
  • 17. Novartis AG
  • 18. Novo Nordisk A/S
  • 19. Pfizer, Inc.
  • 20. Regenxbio Inc.
  • 21. Sanofi SA
  • 22. Takeda Pharmaceutical Company Limited.
  • 23. United Therapeutics Corporation
  • 24. Vertex Pharmaceutical, Inc.

LIST OF FIGURES

  • FIGURE 1. RARE DISEASES TREATMENT MARKET MULTI-CURRENCY
  • FIGURE 2. RARE DISEASES TREATMENT MARKET MULTI-LANGUAGE
  • FIGURE 3. RARE DISEASES TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 4. RARE DISEASES TREATMENT MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL RARE DISEASES TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL RARE DISEASES TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL RARE DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL RARE DISEASES TREATMENT MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL RARE DISEASES TREATMENT MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL RARE DISEASES TREATMENT MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL RARE DISEASES TREATMENT MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL RARE DISEASES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL RARE DISEASES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL RARE DISEASES TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL RARE DISEASES TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL RARE DISEASES TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL RARE DISEASES TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS RARE DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 19. AMERICAS RARE DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES RARE DISEASES TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 21. UNITED STATES RARE DISEASES TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC RARE DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC RARE DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA RARE DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA RARE DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. RARE DISEASES TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 27. RARE DISEASES TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. RARE DISEASES TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL RARE DISEASES TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL RARE DISEASES TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL RARE DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. RARE DISEASES TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL RARE DISEASES TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL RARE DISEASES TREATMENT MARKET SIZE, BY BIOLOGICAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL RARE DISEASES TREATMENT MARKET SIZE, BY NON-BIOLOGICAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL RARE DISEASES TREATMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL RARE DISEASES TREATMENT MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL RARE DISEASES TREATMENT MARKET SIZE, BY CARDIOVASCULAR CONDITIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL RARE DISEASES TREATMENT MARKET SIZE, BY ENDOCRINE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL RARE DISEASES TREATMENT MARKET SIZE, BY HEMATOLOGIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL RARE DISEASES TREATMENT MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL RARE DISEASES TREATMENT MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL RARE DISEASES TREATMENT MARKET SIZE, BY MUSCULOSKELETAL CONDITIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL RARE DISEASES TREATMENT MARKET SIZE, BY NEUROLOGICAL CONDITIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL RARE DISEASES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL RARE DISEASES TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL RARE DISEASES TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL RARE DISEASES TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL RARE DISEASES TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL RARE DISEASES TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL RARE DISEASES TREATMENT MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL RARE DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL RARE DISEASES TREATMENT MARKET SIZE, BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL RARE DISEASES TREATMENT MARKET SIZE, BY GOVERNMENT & REGULATORY BODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL RARE DISEASES TREATMENT MARKET SIZE, BY HOSPITALS & SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL RARE DISEASES TREATMENT MARKET SIZE, BY PATIENT ADVOCACY GROUPS & NONPROFITS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL RARE DISEASES TREATMENT MARKET SIZE, BY PHYSICIAN PRACTICES & OUTPATIENT CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL RARE DISEASES TREATMENT MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS RARE DISEASES TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS RARE DISEASES TREATMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS RARE DISEASES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS RARE DISEASES TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS RARE DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS RARE DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA RARE DISEASES TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA RARE DISEASES TREATMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA RARE DISEASES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA RARE DISEASES TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA RARE DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL RARE DISEASES TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL RARE DISEASES TREATMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL RARE DISEASES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL RARE DISEASES TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL RARE DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA RARE DISEASES TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA RARE DISEASES TREATMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA RARE DISEASES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA RARE DISEASES TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA RARE DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO RARE DISEASES TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO RARE DISEASES TREATMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO RARE DISEASES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO RARE DISEASES TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO RARE DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES RARE DISEASES TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES RARE DISEASES TREATMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES RARE DISEASES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES RARE DISEASES TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES RARE DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES RARE DISEASES TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC RARE DISEASES TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC RARE DISEASES TREATMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC RARE DISEASES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC RARE DISEASES TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC RARE DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC RARE DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA RARE DISEASES TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA RARE DISEASES TREATMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA RARE DISEASES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. AUSTRALIA RARE DISEASES TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. AUSTRALIA RARE DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA RARE DISEASES TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA RARE DISEASES TREATMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA RARE DISEASES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. CHINA RARE DISEASES TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. CHINA RARE DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA RARE DISEASES TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA RARE DISEASES TREATMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 83. INDIA RARE DISEASES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 84. INDIA RARE DISEASES TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. INDIA RARE DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA RARE DISEASES TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. INDONESIA RARE DISEASES TREATMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 88. INDONESIA RARE DISEASES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. INDONESIA RARE DISEASES TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. INDONESIA RARE DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN RARE DISEASES TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. JAPAN RARE DISEASES TREATMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 93. JAPAN RARE DISEASES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. JAPAN RARE DISEASES TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. JAPAN RARE DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA RARE DISEASES TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. MALAYSIA RARE DISEASES TREATMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 98. MALAYSIA RARE DISEASES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. MALAYSIA RARE DISEASES TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. MALAYSIA RARE DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES RARE DISEASES TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. PHILIPPINES RARE DISEASES TREATMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 103. PHILIPPINES RARE DISEASES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 104. PHILIPPINES RARE DISEASES TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. PHILIPPINES RARE DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE RARE DISEASES TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. SINGAPORE RARE DISEASES TREATMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 108. SINGAPORE RARE DISEASES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. SINGAPORE RARE DISEASES TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. SINGAPORE RARE DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA RARE DISEASES TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. SOUTH KOREA RARE DISEASES TREATMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 113. SOUTH KOREA RARE DISEASES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 114. SOUTH KOREA RARE DISEASES TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. SOUTH KOREA RARE DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN RARE DISEASES TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. TAIWAN RARE DISEASES TREATMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 118. TAIWAN RARE DISEASES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. TAIWAN RARE DISEASES TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. TAIWAN RARE DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND RARE DISEASES TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND RARE DISEASES TREATMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 123. THAILAND RARE DISEASES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. THAILAND RARE DISEASES TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. THAILAND RARE DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM RARE DISEASES TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM RARE DISEASES TREATMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 128. VIETNAM RARE DISEASES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. VIETNAM RARE DISEASES TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. VIETNAM RARE DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA RARE DISEASES TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA RARE DISEASES TREATMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA RARE DISEASES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA RARE DISEASES TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA RARE DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA RARE DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK RARE DISEASES TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK RARE DISEASES TREATMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 139. DENMARK RARE DISEASES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 140. DENMARK RARE DISEASES TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. DENMARK RARE DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT RARE DISEASES TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. EGYPT RARE DISEASES TREATMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 144. EGYPT RARE DISEASES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. EGYPT RARE DISEASES TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. EGYPT RARE DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND RARE DISEASES TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. FINLAND RARE DISEASES TREATMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 149. FINLAND RARE DISEASES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 150. FINLAND RARE DISEASES TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 151. FINLAND RARE DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE RARE DISEASES TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. FRANCE RARE DISEASES TREATMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 154. FRANCE RARE DISEASES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. FRANCE RARE DISEASES TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 156. FRANCE RARE DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY RARE DISEASES TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. GERMANY RARE DISEASES TREATMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 159. GERMANY RARE DISEASES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. GERMANY RARE DISEASES TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 161. GERMANY RARE DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL RARE DISEASES TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. ISRAEL RARE DISEASES TREATMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 164. ISRAEL RARE DISEASES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 165. ISRAEL RARE DISEASES TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 166. ISRAEL RARE DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY RARE DISEASES TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. ITALY RARE DISEASES TREATMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 169. ITALY RARE DISEASES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 170. ITALY RARE DISEASES TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 171. ITALY RARE DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS RARE DISEASES TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. NETHERLANDS RARE DISEASES TREATMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 174. NETHERLANDS RARE DISEASES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 175. NETHERLANDS RARE DISEASES TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 176. NETHERLANDS RARE DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA RARE DISEASES TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. NIGERIA RARE DISEASES TREATMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 179. NIGERIA RARE DISEASES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 180. NIGERIA RARE DISEASES TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 181. NIGERIA RARE DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY RARE DISEASES TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. NORWAY RARE DISEASES TREATMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 184. NORWAY RARE DISEASES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 185. NORWAY RARE DISEASES TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 186. NORWAY RARE DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND RARE DISEASES TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. POLAND RARE DISEASES TREATMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 189. POLAND RARE DISEASES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 190. POLAND RARE DISEASES TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 191. POLAND RARE DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR RARE DISEASES TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. QATAR RARE DISEASES TREATMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 194. QATAR RARE DISEASES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 195. QATAR RARE DISEASES TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 196. QATAR RARE DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA RARE DISEASES TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. RUSSIA RARE DISEASES TREATMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 199. RUSSIA RARE DISEASES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 200. RUSSIA RARE DISEASES TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 201. RUSSIA RARE DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA RARE DISEASES TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA RARE DISEASES TREATMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 204. SAUDI ARABIA RARE DISEASES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 205. SAUDI ARABIA RARE DISEASES TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 206. SAUDI ARABIA RARE DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA RARE DISEASES TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH AFRICA RARE DISEASES TREATMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH AFRICA RARE DISEASES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 210. SOUTH AFRICA RARE DISEASES TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 211. SOUTH AFRICA RARE DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN RARE DISEASES TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. SPAIN RARE DISEASES TREATMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 214. SPAIN RARE DISEASES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 215. SPAIN RARE DISEASES TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 216. SPAIN RARE DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN RARE DISEASES TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. SWEDEN RARE DISEASES TREATMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 219. SWEDEN RARE DISEASES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 220. SWEDEN RARE DISEASES TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 221. SWEDEN RARE DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND RARE DISEASES TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. SWITZERLAND RARE DISEASES TREATMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 224. SWITZERLAND RARE DISEASES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 225. SWITZERLAND RARE DISEASES TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 226. SWITZERLAND RARE DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY RARE DISEASES TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. TURKEY RARE DISEASES TREATMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 229. TURKEY RARE DISEASES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 230. TURKEY RARE DISEASES TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 231. TURKEY RARE DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES RARE DISEASES TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES RARE DISEASES TREATMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED ARAB EMIRATES RARE DISEASES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED ARAB EMIRATES RARE DISEASES TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED ARAB EMIRATES RARE DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM RARE DISEASES TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED KINGDOM RARE DISEASES TREATMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM RARE DISEASES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 240. UNITED KINGDOM RARE DISEASES TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 241. UNITED KINGDOM RARE DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 242. RARE DISEASES TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 243. RARE DISEASES TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024